CXCR2 and neoplasm: Higher CXCR2 expression in tumor samples reduced the risk of recurrence in both the TA and TAc groups (univariate test: OR 0.0176, 95% CI [0.001–0.456], p = 0.015; multivariate test: OR 0.003, [0–0.508], p = 0.026).